Trial Profile
Phase II open-label, multi-center study of CP-547, 632, an oral tyrosine kinase inhibitor of VEGFR-2, in subjects with recurrent or persistent small-volume epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs PAN 90806 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 26 Apr 2007 New trial record.